PetVivo Holdings Inc (PETV)

$PETV PetVivo Holdings, Inc. Presenting at the 3rd Annual DealFlow Discovery Conference


https://www.accessnewswire.com/newsroom/en/biotechnology/petvivo-holdings-inc.-presenting-at-the-3rd-annual-dealflow-discovery-conference-1120122

MINNEAPOLIS, MN / ACCESS Newswire / December 23, 2025 / PetVivo Holdings, Inc. (OTCQX:PETV)(OTCID:PETVW), in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.

John Lai, Chief Executive Officer of PetVivo Holdings, Inc., will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about PetVivo Holdings, Inc. and its innovative products at www.petvivo.com.

In the presentation Mr. Lai will be providing information about its lead products, Spryng® with OsteoCushion® Technology and PrecisePRP™. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.

Event Details:

3rd Annual DealFlow Discovery Conference

The Borgata Hotel, Casino & Spa

Atlantic City, NJ

January 28-29, 2026

Investors interested in scheduling a meeting with the [Company Name] management team should request an investor pass to attend the conference (no cost to attend). For more information about Spryng and PrecisePRP, please contact info1@petvivo.com or visit petvivoanimalhealth.com and sprynghealth.com.

$PETV PetVivo Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-89%

https://www.globenewswire.com/news-release/2025/11/25/3194291/0/en/PetVivo-Launches-AI-Platform-Reducing-Veterinary-Client-Acquisition-Costs-by-50-89.html

Revolutionary PetVivo.ai Uses Nine AI Agents to Transform $150B Pet Care Market

MINNEAPOLIS, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on commercializing groundbreaking medical products and therapeutics for horses and companion animals, today announced the launch of PetVivo.ai, a new artificial intelligence platform delivering a customer acquisition cost of $42.53—a 50–89% reduction compared to the $80–$400 typically spent by veterinary practices. The platform generates qualified leads for $3 per pet parent (versus $15–$45 through traditional digital advertising) and uses automated AI engagement to convert these leads into paying customers.

This launch marks a major strategic move for PetVivo Holdings as the company expands from traditional medical device sales—historically generating 30–40% margins—into a high-margin AI Software-as-a-Service (SaaS) model with 80–90% margins, recurring revenue, and significant scalability.

The Problem

Although the pet care industry now exceeds $150 billion annually, veterinary practices face a widening gap in how they reach today’s pet owners. Gen Z and Millennial pet parents account for 57% of all pet owners and expect modern digital experiences, yet many practices still depend on outdated marketing methods such as TV advertising and direct mail.

"Veterinary practices spend $80–$400 per new client depending on their marketing approach," said John Lai, Chief Executive Officer. "Our AI generates qualified leads at just $3 each and converts them automatically. In our beta program, the median practice acquired 47 new clients over six months at a blended customer acquisition cost of $42.53—achieving 50–89% savings without the need for promotional discounting."

The Solution

PetVivo.ai solves this problem through a suite of nine specialized AI agents operating continuously: Client Discovery, Campaign Manager, Engagement, Analytics, Content Creation, Reputation, Compliance, ROI Optimization, and Practice Integration. Together, these agents connect practices with millions of engaged pet parents through a two-sided ecosystem.

Industry-Leading Economics

The platform’s economics were validated in a 50-practice beta program:

Lead Generation: $3 per qualified pet parent (vs. $15–$45 traditional)
Customer Acquisition Cost: $42.53 blended CAC (vs. $80–$400 typical)
Beta Results: 47 new clients median over 6 months (range: 12–124)
Pricing: $1,999/month for the Professional tier
LTV/CAC Ratio: 25:1 (best-in-class)
Payback Period: 1 month
Gross Margins: 80–90%

Market Opportunity

PetVivo.ai targets 30,000 U.S. veterinary practices and more than 100,000 globally. Even conservative adoption forecasts indicate strong scaling potential:

Year 1: 500 practices ? $12M ARR
Year 3: 5,000 practices ? $180M ARR
Year 5: 10,000 practices ? $360M ARR

The Catalyst

The launch serves as a major catalyst for re-valuing the company as it transitions from traditional medical device revenue multiples (1–2x revenue) to AI SaaS multiples (15–30x revenue). Comparable companies such as Salesforce, HubSpot, Veeva Systems, and C3.ai trade at median multiples near 15x, suggesting potential 5–10x valuation upside as PetVivo.ai scales.

"We are currently valued as a medical device company while building an AI SaaS platform with far superior economics," added Mr. Lai. "As revenue grows, we expect meaningful valuation re-rating."

Competitive Advantages

PetVivo.ai holds a first-mover advantage with no direct AI competitors, strong two-sided network effects, and existing relationships with 1,200 veterinary clinic distributors (with plans to target in excess of an additional 7,000). Deep integrations with practice management systems further accelerate adoption and reduce onboarding friction.

Commercial Launch

Following successful beta testing, PetVivo.ai is now fully commercial with open sign-ups at www.petvivo.ai, a 14-day free trial, three pricing tiers, and both direct-sales and self-service onboarding.

$PETV will be presenting at The DealFlow Discovery Conference in Atlantic City, January 28-29, 2026. If you invest in high-growth private or public companies, just putting this on your radar:
I’m involved with this event that brings 150+ growth-stage companies and a big mix of investors into one place for two days.
Accredited investors can attend at no cost. Details here: https://dealflowdiscoveryconference.com/investors/

$PETV PetVivo Holdings Announces Digital Landia’s Publication of Technical Whitepaper Validating AgenticPet AI Framework Under Exclusive 10-Year Licensing Agreement

https://www.globenewswire.com/news-release/2025/11/17/3189065/0/en/PetVivo-Holdings-Announces-Digital-Landia-s-Publication-of-Technical-Whitepaper-Validating-AgenticPet-AI-Framework-Under-Exclusive-10-Year-Licensing-Agreement.html

Comprehensive Documentation Confirms Production-Ready Architecture for PetVivo’s Veterinary Platform Launching Q1 2026

MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on commercializing groundbreaking medical products and therapeutics for horses and companion animals, today announced that its exclusive AI technology partner, Digital Landia Holding Corp., has published a comprehensive technical whitepaper documenting the AgenticPet AI Framework powering PetVivo's B2B veterinary-practice platform.

The whitepaper validates the technical foundation underlying PetVivo's October 2025 exclusive 10-year white-label licensing agreement, providing veterinary professionals, investors, and industry stakeholders with detailed visibility into the multi-agent artificial intelligence architecture that enables transformative clinical and economic benefits for veterinary practices.

TECHNICAL DUE DILIGENCE VALIDATED

"Our October announcement represented months of rigorous technical due diligence," stated John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "We don't partner lightly—especially on decade-long agreements. Today's whitepaper demonstrates exactly what we evaluated: a production-ready AI framework with genuine clinical utility, protected intellectual property, and enterprise-grade architecture capable of serving our entire veterinary network. This isn't a proof of concept; it's fully deployable infrastructure."

FRAMEWORK CAPABILITIES ALIGNED WITH VETERINARY NEEDS

The published whitepaper details technical capabilities that directly address modern veterinary practice challenges, including a 90 to 98 percent reduction in client acquisition costs through seamless pet-parent data flows; universal diagnostic assistance with nine specialized AI agents available across entire clinic patient bases; and enhanced Gen Z market access through a mobile-first consumer experience aligned with digital-native expectations.

INTELLECTUAL PROPERTY PROTECTION

The whitepaper reveals five patent-pending innovations protecting the AgenticPet framework’s core functionality, providing PetVivo with significant competitive advantages under its exclusive 10-year licensing agreement: (1) distributed agent-certification systems; (2) swarm-intelligence coordination protocols; (3) privacy-preserving health-data synthesis; (4) real-time veterinary-integration layers; and (5) adaptive learning pipelines.

ENTERPRISE-READY ARCHITECTURE

The technical documentation demonstrates an architecture specifically designed for professional veterinary-practice requirements, including end-to-end encryption, blockchain audit trails, HIPAA-aligned privacy frameworks, API specifications for practice-management-system integration, automated health-history uploads, and cloud-native infrastructure ensuring over 99.9 percent uptime reliability.

"The whitepaper makes clear that Digital Landia built this framework for veterinarians—not just pet parents," noted Mr. Lai. "The enterprise-grade security, seamless integration specifications, and clinical workflow design demonstrate a deep understanding of veterinary practice operations."

DISTRIBUTION NETWORK READY

PetVivo's established product distribution network, including its partnership with Veterinary Growth Partners (VGP), a prominent veterinary association that has more than 7,300 veterinary professional members, and its established relationships with over 1,000 clinics already using its existing SPRYNG® and PrecisePRP™ product lines, positions the Company to rapidly deploy the AgenticPet platform across a rapidly expanding veterinary industry.

STRATEGIC RATIONALE FOR EXCLUSIVE AGREEMENT

PetVivo's exclusive 10-year licensing structure reflects its confidence in the framework’s competitive positioning and multiple revenue streams, including B2B subscriptions, lead-generation fees, and premium features. Platform network effects increase value as adoption grows, supported by strong demographic tailwinds as Gen Z pet ownership rises approximately 43.5 percent annually.

PARTNERSHIP MILESTONE PROGRESSION

Today's publication marks the third major milestone in the PetVivo–Digital Landia partnership: (1) the March 2025 strategic alliance announcement; (2) the October 2025 exclusive 10-year licensing agreement; and (3) the November 2025 comprehensive technical whitepaper enabling independent evaluation of the framework.

Q1 2026 DUAL-PLATFORM LAUNCH

The documented technical foundation supports a Q1 2026 commercial launch featuring Digital Landia's B2C AgenticPet app and PetVivo's B2B veterinary platform with white-labeled AI diagnostic assistance. Pre-launch registration opens in January 2026.

WHITEPAPER ACCESS

The AgenticPet AI Framework Technical Whitepaper is publicly available at: https://digital-landia.gitbook.io/agentic-pet-whitepaper/.

PetVivo encourages veterinary professionals, investors, and industry stakeholders to review this comprehensive technical documentation.

$PETV Digital Landia Publishes Technical Whitepaper for AgenticPet AI Framework After One Year of Development and Stress Testing

https://www.accessnewswire.com/newsroom/en/banking-and-financial-services/digital-landia-publishes-technical-whitepaper-for-agenticpet-ai-fram-1100917

Unlike Typical Tech Announcements, Whitepaper Documents Already Built and Validated Production System; Five Patent Pending Innovations Ahead of Q1 2026 Launch

MIAMI, FLORIDA / ACCESS Newswire / November 12, 2025 / Digital Landia Holding Corp today announced the public release of its comprehensive AgenticPet AI Framework Technical Whitepaper, marking a significant departure from industry norms by documenting a fully developed and stress tested system rather than theoretical concepts. After one full year of rigorous development, testing, and validation, the company is providing complete transparency into the multi agent architecture powering its revolutionary pet healthcare platform and validating the technology foundation behind its exclusive 10 year licensing partnership with publicly traded PetVivo Holdings, Inc. (OTCQX:PETV).

BUILT FIRST, DOCUMENTED SECOND

"We deliberately reversed the typical Silicon Valley playbook," stated Karim Quazzani, Chief Executive Officer of Digital Landia Holding Corp. "Most tech companies release whitepapers describing what they hope to build someday. We spent an entire year actually building, testing, and validating our framework before publishing a single page of documentation. This whitepaper doesn't describe vaporware or future intentions. It documents a production ready system that has undergone extensive stress testing and real world validation."

The one year development period included architectural design, multi agent system implementation, security framework validation, performance benchmarking under simulated load conditions, and integration testing with veterinary practice management systems.

TECHNICAL ARCHITECTURE REVEALED

The AgenticPet AI Framework employs a sophisticated multi agent architecture featuring nine specialized diagnostic agents operating collaboratively through swarm intelligence coordination. This distributed approach enables autonomous decision making, continuous learning, and multimodal data integration across audio, video, behavioral patterns, IoT sensors, and laboratory results.

The whitepaper provides comprehensive technical specifications including system architecture diagrams, data flow pipelines, API documentation, security protocols, and performance benchmarks validated through extensive testing over the past year.

FIVE PATENT PENDING INNOVATIONS

Digital Landia has secured intellectual property protection for five core innovations developed during the year long build process: distributed agent certification systems, swarm intelligence coordination protocols, privacy preserving health data synthesis, real time veterinary integration layers, and adaptive learning pipelines. These innovations create significant competitive advantages while enabling genuine clinical utility.

STRESS TESTED AND PRODUCTION READY

The yearlong development cycle included rigorous stress testing across multiple dimensions. Load testing simulated millions of concurrent users. Security testing validated encryption protocols and blockchain audit trails. Integration testing confirmed seamless compatibility with existing veterinary practice management systems. Performance testing verified sub second response times under real world conditions.

"Every claim in this whitepaper has been tested and validated," added Karim Quazzani. "We're not promising what we'll build. We're documenting what we've already built and proven works."

VALIDATION OF PETVIVO PARTNERSHIP

Today's publication provides technical validation for the exclusive 10 year B2B licensing agreement announced with PetVivo Holdings in October 2025. PetVivo's extensive due diligence process included hands-on evaluation of the functioning system, not just architectural concepts.

The partnership leverages Digital Landia's AgenticPet B2C freemium app alongside PetVivo's B2B veterinary platform serving over 7,300 clinics through Veterinary Growth Partners. The technical documentation demonstrates how the dual platform architecture enables frictionless data flow, universal diagnostic assistance for all veterinary patients, and dramatic cost reduction of 90 to 98 percent in client acquisition.

Q1 2026 LAUNCH TIMELINE CREDIBLE

The Q1 2026 commercial launch timeline is credible precisely because the technology already exists and has been validated. The remaining months focus on final integrations, user interface refinements, and deployment preparation rather than core technology development.

WHITEPAPER ACCESS

The AgenticPet AI Framework Technical Whitepaper is now publicly available at:

https://digital-landia.gitbook.io/agentic-pet-whitepaper/

$PETV The studies will show dramatic benefits to the dogs, the same as horses. The granulated matrix of heparin, collagen and elastin when injected becomes sponge-like creating a lubricated environment. It also seals the synovial sac and helps the body rebuild the joint. Very different than blocking the nerve as Librela does. It solves the problem! This is why it will take over Librela’s sales!

$PETV Happy new year to this board! I believe Petv will be one of the biggest percentage gainers this year! Why? first the Company is reaping the benefit of its marketing in reaching small animal Vets of the past two years. This required investment in salesmen and several major wholesalers training! Now that ZTS will have problems they stand ready to steal all the $10’s of millions of Librela marketing to bring awareness to Spryng as the better cheaper and totally safe product. This will wake the stock up! Second, the company will complete the ability to be re-listed! I expect by the end of the first quarter and with the ZTS blow up the market cap will explode. 3) sales surging and breakeven and earnings insight for the market to discount. I am long and could trade at anytime!

As a PetVivo salesman, I’d like to discuss why Spryng is a superior choice for treating osteoarthritis in dogs and cats compared to Librela. Let’s examine the facts: Librela’s Concerning Safety Profile Librela, while marketed as an effective treatment, comes with significant risks: • The FDA received over 3,800 reports of side effects through the end of 2023 • The European Medicines Agency received more than 12,300 adverse event reports since 2021 These side effects include: • Ataxia • Seizures • Neurological issues (paresis, recumbency) • Urinary incontinence • Polyuria and polydipsia • In some cases, death or euthanasia Just three weeks ago, the FDA cited Zoetis for potentially underreporting more severe side effects, raising serious concerns about the drug’s safety profile. Problems with Nerve Growth Factor Inhibition Librela’s mechanism of action, inhibiting nerve growth factor (NGF), can lead to: • Increased risk of rapidly progressive osteoarthritis • Potential for osteonecrosis • Systemic effects throughout the body, not just in affected joints • Dramatic increase in systemic oxidative stress, particularly harmful for animals in pre-arthritis and early arthritis stages Spryng: A Superior Alternative Now, let me introduce you to Spryng, a revolutionary treatment that addresses the root cause of osteoarthritis: 1. Mechanism of Action: • Provides a shock-absorbing matrix that mimics natural cartilage • Directly addresses joint mechanics, not just masking pain 2. Safety Profile: • Demonstrated excellent safety in clinical studies • No significant adverse events reported • Localized to the injected joint, minimizing systemic effects 3. Long-lasting Effects: • A single injection can provide benefits for up to 12 months or longer • Compared to Librela’s required monthly injections 4. Cost-effective: • Approximately 50% cheaper for the customer over the course of a year 5. Natural Composition: • Made from purified, naturally-derived proteins and carbohydrates • Mimics the structure and function of natural cartilage 6. Regulatory Advantage: • Classified as a veterinary medical device, not requiring FDA premarket approval 7. Versatility: • Effective for all stages of osteoarthritis • Can be used in multiple joint locations By choosing Spryng, you’re offering your patients a safer, more effective, and cost-efficient solution for managing osteoarthritis. It’s time to move beyond simply masking pain and address the underlying cause of joint issues, providing long-term relief and improved quality of life for our furry companions.

$PETV So when the FDA realizes that ZTS deceived over 50% of the dog and cat owners or close to 30000-400000 , they will totally pull the drug in my opinion! All this info came from Perplexity Pro research and quoted from the human research done by Pfizer, jnj and numerous other major drug companies. The mechanisms are no different in dogs and cats. Just lowering the dose is wrong. It demonstrates through the impact on the redox system that it leads to accelerating the development of the damage to the joint and bone but also the mitochondrial damage. Spring has no side effects and can be used very early and at half price. I guarantee PETV’s distributors will use this info and the Vets fears of being sued as well will cause an immediate switch to Spryng. This could make Spryng a $100 million sales proxy within 2 yrs. This is $99 million of contribution earnings or over $4/ shr. Stock could be explosive.

$PETV This Librela problem is much bigger than ZTS and their analyst community is expecting. 20000 reported major dog incidents reported in the European union means that the side effects are over 10% of the injected dog and cat population. It has to be the same here! The FDA has warned the Vets and now is surveying them and will find this out. Yes ZTS is the PFE( yes their spin out) of the animal health world but even they will have to withdraw in the face of massive class action suits. The Vets have gotten use to this new source of revenue and will quickly replace it with Spryng which solves the arthritis problem not just hide it. No side effects. Thus Petv inherits ZTS $1 billion drug outlook for their FDA approved device! All that marketing money now inures to PETV’s benefit. $75 billion into $11 million!! I guess Petv runs huge or ZTS buys them for a big number, either way this is the stock of early 2025!
Bullish

Exciting update! Scot Cave is now with PetVivo Holdings, Inc. as Field Veterinary Business Development Manager. Watch $PETV! @PetVivo

PETV: delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

why bullish

Moving

Extreme caution here! Price ran up on hype of starting clinical trials for humans for OAK. The market is littered with failed attempts of companies that had far better solutions and they still failed. They will require well over $100 million for all the required pre-clinical and P1, 2 and multiple 3 trials. And the time to completion will definitely not be quick. This is a MINIMUM OF TEN YEARS. PETV has market cap of only about $30 million and they will have to raise over $100 million. what do you think will happen to the share price with that kind of dilution? Yes. . . .we will see many price drops and multiple reverse splits as the company tries to raise money. And short interests know this so I can guarantee that they will be shorting this and driving the price down and down and down. Just take a look at the record of Adam Feuerstein. He broke AMPE that had a much better OAK solution and now the shares are almost worthless after 14 years. And the CEO is one of these know it all arrogant types that is in for a ride to hell. VERY STRONG SELL IMO!

The Company’s management team in cooperation with its human advisory task force anticipates regulatory plans to be completed for new human products implementing the Biomatrix Particulate Technology in the first part of calendar year 2024. The products for human use will be manufactured by PetVivo in its state-of-the-art manufacturing facility in Edina, Minnesota, which is anticipated to be opened in the fourth quarter of 2023.

It's easy, to be honest when you don't say anything. They have an association with a really bad guy, Rich Carozza. He has been with every bad BD on the street. Imay have heard that he is under SEC and FBI investigation. Not sure what he is doing with PETV but it's never good. He is a really bad guy. Beware. IMO

Honest CEO here IMO.

$PETV Live on the Emerging Growth Conference in 30 Minutes

Registration link to interact with the company live here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167551494

$PETV Live on the Emerging Growth Conference Jan 19

Registration link to interact live with the company here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167540089

What is the strike price on the company’s warrants?

Congratulations John Lai on your growth in the markets!!! Good man!

PETV - Friday Rundown, Monday Expectations

Replay $PETV Emerging Growth Conference.

Link to the video is here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166165192

Next Conference October 13
Register Here:
https://goto.webcasts.com/starthere.jsp?ei=1487781&tp_key=e2bca7d62c&sti=twitter

Who do you want to see present?
Tell us here:
www.EmergingGrowth.com/Conference

EGC 17 Replay:
$CANB
$PBIO
$GNTW
$AWX / $AWG
$PETV
$UCASU
$CLSH
$MARK
$CYDY

$PETV Live on the Emerging Growth Conference in 30 minutes!

The Link to Register to Interact Live with the CEO's is here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166135334

Companies Presenting:
$UCASU
$CLSH
$MARK
$CYDY

Presenting now or Previously:
$CANB
$PBIO
$GNTW
$AWG / $AWS / $AWP / $AWX

$PETV Emerging Growth Conference 17 Starts in 1 hour!

The Link to Register to Interact Live with the CEO's is here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166135334

Companies Presenting:
$CANB
$PBIO
$GNTW
$AWG / $AWS / $AWP / $AWX
$PETV
$UCASU
$CLSH
$MARK
$CYDY

$PETV PetVivo CEO Live on the Emerging Growth Conference on September 29, 2021

Registration link here to interact Live:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166052950

Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference

$PETV Replay Emerging Growth Conference 14
Get the link
and...

Register for the next Conference on 9/1 here...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165547337

Who do you want to see present?

EGC 14 Presenters for Replay:
$NSAV - VirtuaBroker
$RYAH $RYAHF
$PETV
$ACXP
$PBIO
$TOMDF
$GRYN
$INND
$SNMN
$WNBD

$PETV Live on the Emerging Growth Conference in 30 minutes!

Link to watch the Conference here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165497793

Other Companies Presenting:
$ACXP
$PBIO
$TOMDF
$GRYN
$INND
$SNMN
$WNBD

Presented Earlier:
$NSAV
$RYAH $RYAHF

$PETV Live on the Emerging Growth Conference this Wednesday August 18, 2021.

The registration link so you can watch the live presentation is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165458105

$PETV PetVivo Congratulations on the NASDAQ Uplist! CEO Live on the Emerging Growth Conference on August 18, 2021

Registration Link here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165396738


Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference

PETV moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

$PETV PetVivo Presenting Live on the Emerging Growth Conference on August 18, 2021

Registration Link Here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165369149

Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference

1for 4 reverse.

Nasdaq?

PETV: effective Dec. 30,2020 a one for 4 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

ANOTHER RS coming. Tomorrow at the bell this ticker has a 1 for 4 RS. Hell...they just pulled a RS a year ago.

Share holders on 12/30 won't be able to sell until well into the first week of Jan, maybe later.

10,000 shares become 2500. Nice..............

Congrats to John Lai!!!

NEWS: $PETV nScrypt Bioprints PetVivo® Biomaterial for Orthopedic Implants

Orlando, Florida, Oct. 20, 2020 (GLOBE NEWSWIRE) -- nScrypt is excited to announce the successful bioprinting of PetVivo ® Holdings’ biomaterial, using nScrypt’s 3D Bio-Fabrication Tool (BAT). The nScrypt BAT technology was able to easily 3D ...

Got this from PETV - nScrypt Bioprints PetVivo® Biomaterial for Orthopedic Implants

New video Interview

PETV a nine for ten reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

$PETV - PetVivo Up 102% Last Week on $3 Price Target Issued 

PetVivo’s Holdings, Inc.  (PETV: OTCQB)  - CEO, John Lai, discusses the new and revolutionary treatment of osteoarthritis by administering PetVivo’s injectable product

See the video here:

PETV Daily Chart...MACD moving up..

News out --- PetVivo Holdings, Inc. Featured in New Research Update
Press Release | 09/26/2019
MINNEAPOLIS, MN, Sept. 26, 2019 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.

The updated report provides an overview of recent events, new initiatives, and the company’s valuation relative to its peer group. The sponsored research update also carries a rating and a price target and can be accessed at its partner site, www.GoldmanResearch.com.

Marble Arch Research notes that, “With a number of competitive advantages in the space, a deep product pipeline and IP portfolio, combined with a clever financial model, we believe that the Company can enjoy hockey-stick type sales growth in the next 2-3 years. Plus, its new technology licensing for CBD use could prove to be a sleeper and a very profitable engine for PetVivo. Our target is based upon a 5.5x sales P/S multiple, similar to its peer group, and affirmed by a Net Present Value (NPV) calculation. In our view, the current price reflects an attractive entry point.”

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of eighteen patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs and horses called Kush® is scheduled for launch later this fiscal year.

The Company recently exclusively licensed its mucoadhesive technology to a strategic partner, Emerald Organic Products, Inc., for use of CBD in the human nutraceutical market. The Company will also be seeking additional licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:
John Lai
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216

I found this on their website...very interesting.

One Injection Restored Mobility in Their Lives for Years – $PETV

https://petvivo.com/

Interesting Development.

Emerald Organic Products, Inc. (EMOR) Announces Exclusive Licensing Agreement With PetVivo Holdings Inc. (PETV).

“In the right hands, this product has the potential to revolutionize the vitamin and CBD market place and we are confident we found the right team partner in Emerald.”

http://marijuanastockreview.com/emerald-organic-products-inc-emor-announces-exclusive-licensing-agreement-with-petvivo-holdings-inc-petv/

Anyone have an idea if PETCO joint goop is viable and soon to report initial sales?

The term someone shed a light down the crack.

Wow.

The term "fallen between the cracks" comes to mind. Studying now.

Percentage drop appears like a typical toxic unwinding, but there's no volume so doubt that was the cause.